BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Trial ID or NCT#

NCT01354431

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Official Title

A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component* Previous treatment with at least one anti-angiogenic agent* Progressed within 6 months of study enrollment* Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease* Must have available tumor tissue for submission* Subjects must also meet various laboratory parameters for inclusion
Exclusion Criteria:
  1. * Subjects with any active autoimmune disease or a history of known autoimmune disease
    1. Other protocol-defined inclusion/exclusion criteria apply
View All Criteria
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov